Abstract
Canvas opinion around the medical and scientific communities as to the therapeutic areas presenting the greatest challenges for the pharmaceutical industry in the 21st Century, and the chances are the CNS disease (a term covering a broad spectrum of pathologies), oncology and HIV infection will be at the top of many people's lists. Whilst some significant advances have occurred in these therapeutic areas over the last decade, the continuing morbidity and mortality associated with a diagnosis in these areas confirms the need for new therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 102-106 |
| Number of pages | 5 |
| Journal | European Pharmaceutical Contractor |
| Issue number | SPRING |
| Publication status | Published - Mar 2004 |
Fingerprint
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
CNS, oncology and HIV clinical trials : Current trends and future prospects. / Collis, Phil; McVie, Gordon.
In: European Pharmaceutical Contractor, No. SPRING, 03.2004, p. 102-106.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CNS, oncology and HIV clinical trials
T2 - Current trends and future prospects
AU - Collis, Phil
AU - McVie, Gordon
PY - 2004/3
Y1 - 2004/3
N2 - Canvas opinion around the medical and scientific communities as to the therapeutic areas presenting the greatest challenges for the pharmaceutical industry in the 21st Century, and the chances are the CNS disease (a term covering a broad spectrum of pathologies), oncology and HIV infection will be at the top of many people's lists. Whilst some significant advances have occurred in these therapeutic areas over the last decade, the continuing morbidity and mortality associated with a diagnosis in these areas confirms the need for new therapies.
AB - Canvas opinion around the medical and scientific communities as to the therapeutic areas presenting the greatest challenges for the pharmaceutical industry in the 21st Century, and the chances are the CNS disease (a term covering a broad spectrum of pathologies), oncology and HIV infection will be at the top of many people's lists. Whilst some significant advances have occurred in these therapeutic areas over the last decade, the continuing morbidity and mortality associated with a diagnosis in these areas confirms the need for new therapies.
UR - http://www.scopus.com/inward/record.url?scp=4444306707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444306707&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:4444306707
SP - 102
EP - 106
JO - EPC - European Pharmaceutical Contractor
JF - EPC - European Pharmaceutical Contractor
SN - 1364-369X
IS - SPRING
ER -